Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

Executive Summary

New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.

Advertisement

Related Content

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells
Autolus Raises $80m To Take T-Cell Engineering To The Next Level
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Too Sick For CAR-T? Kite Reports Cerebral Edema Death
Celyad VP On IP Issues, Development Timelines For CAR-T Therapies
Engineered T-Cell Company Raises $56m And Lands New CEO
New kid on the CAR-T block: Syncona/UCL form Autolus

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC122943

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel